Abstract
Venlafaxine (VLX) could be pumped out of the brain by P-glycoprotein (P-gp). Moreover, the expression of P-gp distributed in blood–brain barrier could be significantly induced by VLX. Thus, P-gp could be considered as the nature barrier for delivering of VLX to the brain. The aim of this study was to investigate whether the efflux function and increased expression of P-gp could be reversed by utilizing solid lipid nanoparticles (SLN). VLX solid lipid nanoparticles (VLX − SLN) were prepared and evaluated. Pharmacokinetics and brain distribution of VLX in different formulations were conducted after oral or intravenous administration. P-gp efflux function to VLX was evaluated by the brain uptake amount of VLX, while P-gp expression was investigated by Western blotting. Results indicated that the entrapment, mean size and zata potential of VLX − SLN was 74.9 ± 3.0 %, 186.3 ± 69.26 nm and −22.8 ± 7.78 mv, respectively. After vein injection of VLX formulations, the brain uptake amount of VLX from VLX − SLN was significantly higher than that of VLX solution, VLX solution with empty SLN (VLX+ empty SLN) and VLX solution with Verapamil (VLX + Ver), respectively. Furthermore, the protein mass of P-gp in VLX − SLN treated group was the lowest among all the investigated groups. These results indicated that SLN could overcome P-gp and achieve brain target by intravenous administration.
Similar content being viewed by others
References
Amin, M.L. 2013. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7: 27–34.
Bachmeier, C.J., D. Beaulieu-Abdelahad, N.J. Ganey, M.J. Mullan, and G.M. Levin. 2011. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharmaceutics & Drug Disposition 32: 233–244.
Bhalekar, M.R., A.R. Madgulkar, D.D. Sheladiya, S.J. Kshirsagar, N.D. Wable, and S.S. Desale. 2008. Statistical optimization of sustained release venlafaxine hci wax matrix tablet. Indian Journal of Pharmaceutical Sciences 70: 472–476.
Bymaster, F.P., L.J. Dreshfield-Ahmad, P.G. Threlkeld, J.L. Shaw, L. Thompson, D.L. Nelson, S.K. Hemrick-Luecke, and D.T. Wong. 2001. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25: 871–880.
Colabufo, N.A., F. Berardi, M.G. Perrone, E. Capparelli, M. Cantore, C. Inglese, and R. Perrone. 2010. Substrates, inhibitors and activators of P-glycoprotein: candidates for radiolabeling and imaging perspectives. Current Topics in Medicinal Chemistry 10: 1703–1714.
Dong, X., and R.J. Mumper. 2010. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine 5: 597–615.
Dwibhashyam, V.S., and A.N. Nagappa. 2008. Strategies for enhanced drug delivery to the central nervous system. Indian Journal of Pharmaceutical Sciences 70: 145–153.
Gaur, P.K., S. Mishra, M. Bajpai, and A. Mishra. 2014. Enhanced oral bioavailability of efavirenz by solid lipid nanoparticles: In vitro drug release and pharmacokinetics studies. Biomed Research International 2014: 363404.
Ghadiri, M., S. Fatemi, A. Vatanara, D. Doroud, A.R. Najafabadi, M. Darabi, and A.A. Rahimi. 2012. Loading hydrophilic drug in solid lipid media as nanoparticles: Statistical modeling of entrapment efficiency and particle size. International Journal of Pharmaceutics 424: 128–137.
Haque, S., S. Md, M. Fazil, M. Kumar, J.K. Sahni, J. Ali, and S. Baboota. 2012. Venlafaxine loaded chitosan NPs for brain targeting: Pharmacokinetic and pharmacodynamic evaluation. Carbohydrate Polymers 89: 72–79.
Kakkar, V., A.K. Mishra, K. Chuttani, and I.P. Kaur. 2013. Proof of concept studies to confirm the delivery of curcumin loaded solid lipid nanoparticles (C-SLNs) to brain. International Journal of Pharmaceutics 448: 354–359.
Karlsson, L., C. Hiemke, B. Carlsson, M. Josefsson, J. Ahlner, F. Bengtsson, U. Schmitt, and F.C. Kugelberg. 2011. Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacology 215: 367–377.
Karlsson, L., U. Schmitt, M. Josefsson, B. Carlsson, J. Ahlner, F. Bengtsson, F.C. Kugelberg, and C. Hiemke. 2010. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. European Neuropsychopharmacology 20: 632–640.
Kaur, I.P., R. Bhandari, S. Bhandari, and V. Kakkar. 2008. Potential of solid lipid nanoparticles in brain targeting. Journal of Controlled Release 127: 97–109.
Loscher, W., and H. Potschka. 2005. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2: 86–98.
Miao, Q., Q. Liu, C. Wang, Q. Meng, X. Guo, H. Sun, J. Peng, X. Ma, T. Kaku, and K. Liu. 2013. Inhibitory effect of 1alpha,25-dihydroxyvitamin D(3) on excretion of JBP485 via organic anion transporters in rats. European Journal Of Pharmaceutical Sciences 48: 351–359.
Misra, A., S. Ganesh, A. Shahiwala, and S.P. Shah. 2003. Drug delivery to the central nervous system: a review. Journal of Pharmacy & Pharmaceutical Sciences 6: 252–273.
Parhi, R., and P. Suresh. 2012. Preparation and characterization of solid lipid nanoparticles-a review. Current Drug Discovery Technologies 9: 2–16.
Ramakrishnan, P. 2003. The Role of P-glycoprotein in the Blood-Brain Barrier. The Einstein Quarterly Journal of Biology and Medicine 19: 160–165.
Schinkel, A.H. 1999. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Advanced Drug Delivery Reviews 36: 179–194.
Scotto, K.W. 2003. Transcriptional regulation of ABC drug transporters. Oncogene 22: 7496–7511.
Stahl, S.M., M.M. Grady, C. Moret, and M. Briley. 2005. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums 10: 732–747.
Sugimoto, H., H. Hirabayashi, Y. Kimura, A. Furuta, N. Amano, and T. Moriwaki. 2011. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats. Drug Metabolism and Disposition 39: 8–14.
Thomas, H., and H.M. Coley. 2003. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10: 159–165.
Uhr, M., M.T. Grauer, and F. Holsboer. 2003. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biological Psychiatry 54: 840–846.
Wohlfart, S., S. Gelperina, and J. Kreuter. 2012. Transport of drugs across the blood-brain barrier by nanoparticles. Journal of Controlled Release 161: 264–273.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zhou, Y., Zhang, G., Rao, Z. et al. Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. Arch. Pharm. Res. 38, 1325–1335 (2015). https://doi.org/10.1007/s12272-014-0539-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-014-0539-6